Cyclic HPMPC is safe and effective against systemic guinea pig cytomegalovirus infection in immune compromised animals

Antiviral Research

Volumn 47, Issue 2, 2000, Pages 103-109

  Bourne, N ^a   Bravo, F J ^a   Bernstein, D I ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Antiviral; CHPMPC; Cytomegalovirus; Guinea pig; Immune compromised

Indexed keywords

1 [(2 HYDROXY 2 OXO 1,4,2 DIOXAPHOSPHORINAN 5 YL)METHYL]CYTOSINE; ANTIVIRUS AGENT; CIDOFOVIR; CYCLOPHOSPHAMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC THERAPY; ANTIVIRAL ACTIVITY; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GUINEA PIG; HUMAN; IMMUNE DEFICIENCY; MALE; MORTALITY; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; TISSUE DISTRIBUTION; TREATMENT OUTCOME; VIRUS LOAD; VIRUS REPLICATION;

ANIMAL; ANTIVIRAL AGENTS; CYCLOPHOSPHAMIDE; CYTOMEGALOVIRUS INFECTIONS; CYTOSINE; GUINEA PIGS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FUNCTION TESTS; LIVER; LIVER FUNCTION TESTS; LUNG; MALE; ORGANOPHOSPHORUS COMPOUNDS; SPLEEN; SUPPORT, U.S. GOV'T, P.H.S.; TREATMENT OUTCOME; VIRUS REPLICATION;

EID: 0033833668     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(00)00100-5     Document Type: Article

References (27)

1. Andrei G., Snoeck R., Schols D., Goubau P., Desmyter J., De Clercq E. Comparative activity of selected antiviral compounds against clinical isolates of human cytomegalovirus. Eur. J. Clin. Infect. Dis. 10:1991;1026-1033.
2. Aquino-de Jesus M.J.C., Griffith B.P. Cytomegalovirus infection in immunocompromised guinea pigs: a model for testing antiviral agents in vivo. Antiviral Res. 12:1989;181-194.
3. Bia F.J., Lucia H.L., Bia M.J., Vine W., Tuttle A. Effects of cyclosporine on the pathogenesis of primary cytomegalovirus infection in the guinea pig. Intervirology. 24:1985;154-165.
4. Bischofberger N., Hitchcock M.J.M., Chen M.S., Barkhimer D.A., Cundy K.C., Kent K.M., Lacy S.A., Lee W.A., Li Z.-H., Mendel D.B., Smee D.F., Smith J.L. 1-[((s)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl] cytosine, an intracellular prodrug for (s)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine with improved therapeutic index in vivo. Antimicrob. Agents Chemother. 38:1994;2387-2391.
5. Bratcher D.F., Bourne N., Bravo F.J., Schleiss M.R., Slaoui M., Myers M.G., Bernstein D.I. Effect of passive antibody on congenital cytomegalovirus infection in guinea pigs. J. Infect. Dis. 172:1995;944-950.
6. Bravo F.J., Stanberry L.R., Kier A.B., Vogt P.E., Kern E.R. Evaluation of HPMPC therapy for primary and recurrent genital herpes in mice and guinea pigs. Antiviral Res. 21:1993;59-71.
7. Bronson J.J., Ghazzouli I., Hitchcock M.J., Webb R.R., Martin J.C. Synthesis and antiviral activity of the nucleotide analogue (s)-1-[3-hydroxy-2-phosphonylmethoxy)propyl]cytosine. J. Med. Chem. 32:1989;1457-1463.
8. Cundy K.C., Bidgood A.M., Lynch G., Shaw J.P., Lee W.A. Pharmacokinetics, bioavailibility, metabolism, and tissue distribution of cidofovir (HPMPC) and cyclic HPMPC in rats. Drug Metab. Dispos. 24:1996;745-752.
9. Cundy K.C., Barditch-Crovo P., Petty B.G., Ruby A., Redpath M., Jaffe H.S., Lietman P.S. Clinical pharmacokinetics of 1-[((s)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl]cytosine in human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 43:1999;271-277.
10. De Clercq E., Holy A. Efficacy of (s)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine in various models of herpes simplex virus infection in mice. Antimicrob. Agents Chemother. 35:1991;701-706.
11. Demmler G.J. Congenital cytomegalovirus infection and disease. Semin. Pediatr. Infect. Dis. 10:1999;195-200.
12. Drew W.L., Lalezari J.P. Cytomegalovirus: Disease syndromes and treatment. Curr. Clin. Top. Infect. Dis. 19:1999;16-29.
13. Fong C.K.Y., Cohen S.D., McCormick S., Hsiung G.D. Antiviral effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine against cytomegalovirus infection in a guinea pig model. Antiviral Res. 7:1987;11-23.
14. Griffith B.P., Lucia H.L., Bia F.J., Hsiung G.D. Cytomegalovirus-induced mononucleosis in guinea pigs. Infect. Immun. 32:1981;857-863.
15. Harrison C.J., Myers M.G. Peripheral blood mononuclear cell-mediated cytolytic activity during cytomeagalovirus (CMV) infection of guinea pigs. J. Med. Virol. 25:1988;222-228.
16. Hitchcock M.J., Lacy S.A., Lindsey J.R., Kern E.R. The cyclic congener of cidofovir has reduced nephrotoxicity in three species. Antiviral Res. 26:1995;A358.
17. Kern E.R., Palmer J., Hartline C., Vogt P.E. Comparison of efficacy and toxicity of HPMPC and cyclic HPMPC in animal models for severe herpesvirus infections. Antiviral Res. 26:1995;A329.
18. Lalezari J.P, Drew W.L., Glutzer E., James C., Miner D., Flaherty J., Fisher P.E., Cundy K., Hannigan J., Martin J.C., Jaffe H.S. (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine (cidofovir):results of a phase I/II study of a novel antiviral nucleotide analogue. J. Infect. Dis. 171:1995;788-796.
19. Lalezari J.P., Stagg R.J., Kuppermann B.D., Holland G.N., Kramer F., Ives D.V., Youle M., Robinson M.R., Drew W.L., Jaffe H.S. Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized, controlled trial. Ann. Inter. Med. 126:1997;257-263.
20. Li S.B., Yang Z.H., Feng J.S., Fong C.K.Y., Lucia H.L., Hsiung G.D. Activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) against guinea pig cytomegalovirus infection in cultured cells and in guinea pigs. Antiviral Res. 13:1990;237-252.
21. Macdonald J.C., Torriani F.J., Morse L.S., Karavellas M.P., Reed J.B., Freeman W.R. Lack of reactivation of cytomegalovirus (CMV) retinitis after stopping CMV maintenance therapy in AIDS patients with sustained elevations in CD4 T cells in response to highly active antiretroviral therapy. J. Infect. Dis. 177:1998;1182-1187.
22. Mendel D.B., Cihlar T., Moon K., Chen M.S. Conversion of 1-[((s)-2-hydroxy-2-oxo-1,4,2-dioxaphosphrinan-5-yl)methyl]cytosine to cidofovir by an intracellular cyclic CMP phopphodiesterase. Antimircrob. Agents Chemother. 41:1997;641-646.
23. Neyts J., Balzarini J., Naesens L., De Clercq E. Efficacy of (s)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine and 9-(1,3-dihydroxy-2propoxymethyl)guanine for the treatment of murine cytomegalovirus infection in severe combined immunodeficiency mice. J. Med. Virol. 37:1992;67-71.
24. Polis M.A., Spooner K.M., Baird B.F., Manischewitz J.F., Jaffe H.S., Fisher P.E., Falloon J., Daver R.T. Jr., Kovacs J.A., Walker R.E., Whitcup S.M., Nussenblatt R.B., Lane H.C., Masur H. Anticytomegaloviral activity and safety of cidofovir in patients with human immunodeficiency virus infection and cytomegalovirus viuria. Antimicrob. Agents Chemother. 39:1995;882-886.
25. Safrin S., Cherrington J., Jaffe H.S. Cidofovir: Review of current and potential clinical uses. Adv. Exp. Med. Biol. 458:1999;111-120.
26. Sia I., Patel G.R. New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients. Clin. Microbiol. Rev. 13:2000;83-121.
27. Whitcup S.M. Cytomegalovirus retinitis in the era of highly active antiretroviral therapy. JAMA. 283:2000;653-657.